Crimean-Congo hemorrhagic fever in Europe: current situation calls for preparedness by Maltezou, H. C. et al.
1www.eurosurveillance.org
Perspectives
Crimean-Congo hemorrhagic fever in Europe: current 
situation calls for preparedness
H C Maltezou (helen-maltezou@ath.forthnet.gr)1, L Andonova2, R Andraghetti3, M Bouloy4, O Ergonul5, F Jongejan6,
N Kalvatchev7, S Nichol8, M Niedrig9, A Platonov10, G Thomson11, K Leitmeyer12, H Zeller12
1. Hellenic Center for Diseases Control and Prevention, Athens, Greece
2. Medical University, Sofia, Bulgaria
3. World Health Organization, Copenhagen, Denmark
4. Institut Pasteur, Paris, France
5. Marmara University, Istanbul, Turkey
6. Utrecht Centre for Tick-borne Diseases, Utrecht University, Utrecht, the Netherlands
7. National Centre of Infectious and Parasitic Diseases, Sofia, Bulgaria
8. Centers of Disease Control and Prevention, Atlanta, United States
9. Robert Koch Institute, Berlin, Germany
10. Central Research Institute of Epidemiology, Moscow, Russian Federation
11. Health Protection Agency, London, United Kingdom
12. European Centre for Disease Control and Prevention, Stockholm, Sweden
Citation style for this article: 
Citation style for this article: Maltezou HC, Andonova L, Andraghetti R, Bouloy M, Ergonul O, Jongejan F, Kalvatchev N, Nichol S, Niedrig M, Platonov A, Thomson G, 
Leitmeyer K, Zeller H. Crimean-Congo hemorrhagic fever in Europe: current situation calls for preparedness. Euro Surveill. 2010;15(10):pii=19504. Available online: 
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19504
This article has been published on 11 March 2010
During the last decade Crimean-Congo hemorrhagic 
fever (CCHF) emerged and/or re-emerged in several 
Balkan countries, Turkey, southwestern regions of the 
Russian Federation, and the Ukraine, with consider-
able high fatality rates. Reasons for re-emergence of 
CCHF include climate and anthropogenic factors such 
as changes in land use, agricultural practices or hunt-
ing activities, movement of livestock that may influ-
ence host-tick-virus dynamics. In order to be able to 
design prevention and control measures targeted 
at the disease, mapping of endemic areas and risk 
assessment for CCHF in Europe should be completed. 
Furthermore, areas at risk for further CCHF expansion 
should be identified and human, vector and animal 
surveillance be strengthened.
Introduction 
Crimean-Congo hemorrhagic fever (CCHF) is an acute, 
highly-contagious viral zoonosis transmitted to 
humans mainly by ticks of the genus Hyalomma, but 
also through direct contact with blood or tissues of 
viraemic hosts. In humans CCHF typically presents 
with high fever of sudden onset, malaise, severe head-
ache and gastrointestinal symptoms. Prominent hem-
orrhages may occur in late stages of the disease with 
published fatality rates ranging from 10% to 50% [1,2]. 
The disease is endemic in parts of Africa, Asia, the 
Middle East and eastern Europe. Main animal hosts 
include a number of domestic animals such as cat-
tle, sheep, goats, and hares. CCHF has the potential 
to cause community and nosocomial outbreaks. Due 
to the high case fatality rates and difficulties in treat-
ment, prevention, and control, CCHF is a disease which 
should be notified immediately to public health author-
ities in the European Union (EU). CCHF virus is also in 
the list of agents for which the Revised International 
Health Regulations of 2005 call for implementation of 
the decision algorithm for risk assessment and pos-
sible notification to the World Health Organization 
(WHO) [3]. 
In Europe, CCHF is currently only endemic in Bulgaria, 
however during the last decade an increased number 
of CCHF cases and outbreaks have been recorded in 
other countries in the region such as Albania, Kosovo, 
Turkey, and the Ukraine as well as south-western 
regions of the Russian Federation [4-9]. In June 2008, 
the first case was registered in Greece [10]. In response 
to this situation, the European Centre for Disease 
Prevention and Control (ECDC) invited a group of CCHF 
experts to review the situation of CCHF in Europe and 
to consult on interventions necessary to strengthen 
preparedness and response at the European level [11].
This article provides an update on the current situa-
tion of CCHF in Europe, and emphasises existing pre-
vention and control capacities within the EU. Aspects 
relevant to strengthen preparedness for CCHF are also 
discussed. 
CCHF situation in Europe 
CCHF is endemic in Bulgaria since the 1950’s, when a 
large outbreak occurred from 1954 to 1955 with 487 
notified cases mainly in the Shumen area in north-east 
Bulgaria. In total, 1,568 CCHF cases were notified in 
Bulgaria from 1953 to 2008, with an overall case fatal-
ity rate of 17% [4]. Endemic areas are confined to the 
vicinity of Shumen, Razgrad, Veliko Tarnovo, Plovdiv, 
Pazardjik, Haskovo, Kardjali, and Bourgas, however 
in April 2008 a cluster of six probable cases occurred 
in Gotse Delchev in the south-western province 
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Blagoevgrad near the border with Greece, an area 
considered of low CCHF endemicity until recently [5]. 
During the last decade, CCHF outbreaks have also been 
noted in Albania in 2001 and 2003, and in Kosovo in 
2001 [6,7].  
In Turkey, the first symptomatic human CCHF cases 
were noted in 2002, however, serologic evidence of 
enzootic CCHF virus circulation as well as limited evi-
dence of CCHF infections among humans (2.4% among 
1,100 tested humans) has been found since the 1970’s 
[4]. Starting in 2003, Turkey has experienced an 
expanding outbreak with increasing numbers of noti-
fied cases and associated fatalities (2002: 17/0; 2003: 
133/6; 2004: 249/13; 2005: 266/13; 2006: 438/27; 
2007: 713/33; 2008: 1315/63; 2009: 1300/62) [4,12]. 
Overall, there are more than 4,400 recorded laboratory 
confirmed CCHF cases in this country, mainly among 
residents in rural areas in north-central and north-
east Anatolia [4,8,12]. Within the CCHF endemic areas, 
there are hyperendemic areas where one out of every 
five residents and one out of every two residents with 
a history of tick bite has antibodies against CCHF virus 
[13]. A predictive map model using satellite-based cli-
mate data and high-resolution vegetation images from 
Turkey from 2003 to 2006 revealed that areas with 
higher CCHF reporting were significantly associated 
with zones of high climate suitability for Hyalomma 
ticks and high rate of fragmentation of agricultural 
land [13]. 
In Greece, a serosurvey conducted between 1981 and 
1988 among 3,388 rural residents from across the 
country showed 1% seroprevalence rate against CCHF 
virus [4]. More than 400 cases with a CCHF compatible 
clinical syndrome have tested negative for CCHF virus 
in this country since 1982, therefore, the seropreva-
lence rate of 1% was attributed to the non-pathogenic 
AP-92 strain and not to the pathogenic Balkan CCHF 
virus strain. A number of the cases tested for CCHF 
were finally diagnosed as hemorrhagic fever with renal 
syndrome (HFRS), leptospirosis and ricketsial infec-
tions. Other diagnoses were meningococcal menin-
gitis and unspecified bacterial sepsis. The first CCHF 
case was recorded in June 2008 in a woman with a tick 
bite working in agriculture near the city of Komotini 
in north-eastern Greece [10]. This town is situated 
within a few kilometres distance from there where the 
Bulgarian cluster occurred in 2008 [5]. A seroepidemi-
ological study for CCHF virus among local population 
and animals are underway in northern Greece.      
After nearly 27 years without any human cases, CCHF 
re-emerged in the south-western regions of the Russian 
Federation in 1999. Outbreaks have been reported in 
Astrakhan, Rostov and Volgograd Provinces, Krasnodar 
and Stavropol Territories, Kalmykia, Dagestan and 
Ingushetia Republics. Between 2000 and 2009 more 
than 1,300 clinical cases were diagnosed in the 
Russian Federation with an overall fatality rate of 3.2% 
for the period from 2002-2007 [4]. Most cases occurred 
among residents of rural areas in the Southern Federal 
Distinct. The largest number of cases was registered 
in Stavropol Territory, Kalmykia Republic and Rostov 
Province, where the mean annual CCHF incidence 
rate was 1.7, 10.1, and 0.7 cases per 100,000 popula-
tion, respectively. During 2008 alone, the incidence in 
Stavropol Territory increased by 1.3 times, and was the 
highest recorded in this region during the last decade 
[4,9,14]. In 2009, CCHF cases were also reported from 
Georgia, Kazakhstan, Tajikistan, Iran, and Pakistan 
[15].  
CCHF emergence and/or re-emergence in south-eastern 
Europe and neighboring countries is attributed to cli-
mate and ecologic changes and anthropogenic factors 
such as changes in land use, agricultural practices, 
hunting activities, and movement of livestock, that 
may have an impact on ticks and hosts and accordingly 
on CCHF epidemiology [1,2]. The geographic distribu-
tion of CCHF coincides with that of Hyalomma ticks. 
H. marginatum, the main CCHF virus vector in Europe, 
is found in Albania, Bulgaria, Cyprus, France, Greece, 
Italy, Kosovo, Moldavia, Portugal, Romania, Russia, 
Serbia, Spain, Turkey, and the Ukraine. In 2006 it was 
detected for the first time in the Netherlands and in 
southern Germany [16,17]. Given the wide distribution 
of its vector, the numerous animals that can serve as 
hosts, and the favorable climate and ecologic con-
ditions in several European countries bordering the 
Mediterranean Sea, it is possible that the occurrence 
of CCHF will expand in the future. A model that stud-
ied various climate scenarios on the habitat areas of 
different ticks, showed that a rise in temperature and 
a decrease in rainfall in the Mediterranean region will 
result in a sharp increase in the suitable habitat areas 
for H. marginatum and its expansion towards the north, 
with the highest impact noted at the margins of its cur-
rent geographic range [18]. 
Current prevention and control in Europe 
Several elements relating to laboratory diagnosis, sur-
veillance and therapy of CCHF should be addressed in 
order to increase preparedness capacity in Europe and 
to design appropriate prevention and control measures. 
Laboratory diagnosis
In 2008 there were 20 laboratories with diagnostic 
capacities for CCHF virus in Europe: 14 in EU Member 
States, eight in the endemic regions of the Russian 
Federation, and one in Turkey. Most of them used 
immunofluorescence assays (IFA), ELISA, and/or molec-
ular methods to diagnose CCHF whereas eight among 
them were also able to isolate CCHF virus [11], a BSL-4 
containment agent. Limitations for diagnosing CCHF 
concern both the limited diagnostic capacities in sev-
eral endemic areas as well as difficulties in the inter-
national transfer of samples for logistic and economic 
reasons. However, rapid and easy tests are needed to 
guide initial therapeutic decisions for the patient. 
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Surveillance
Currently, there are no standardised case definitions for 
CCHF notification and contact tracing within European 
countries [19]. Recent cases of nosocomial acquisition 
of CCHF in health care workers were well documented 
[6,8,20]. These cases underline the need for educat-
ing health-care workers about the modes of getting 
infected with CCHF virus and for strict implementa-
tion of infection control measures within health-care 
facilities, and the importance of providing adequate 
resources to do so [1,2].       
Therapy
The World Health Organization (WHO) recommends rib-
avirin for the treatment of CCHF cases [21,22]. Ribavirin 
appears to be more effective when introduced early 
in the course of illness [23]. Evidence of its efficacy is 
based on in vitro data and on limited observations in 
humans [24-26]. Randomised controlled trials have not 
been conducted so far, and ethical issues concerning 
the use of a control group remain a major obstacle for 
this [27]. Severity of infection, duration of illness prior 
to initiation of therapy, and route of administration may 
impact the clinical outcome of CCHF cases. On indi-
vidual country level, recommendations for treatment 
of CCHF cases with ribavirin existed in 2008 in Turkey, 
Russia, Bulgaria, and Greece. In Bulgaria, in addition, 
specific hyperimmune globulin collected from conva-
lescent CCHF cases is used for prophylaxis and treat-
ment and an inactivated suckling mouse brain vaccine 
is in use since the 1970’s for high-risk groups living in 
CCHF endemic regions [28]. There is no vaccine against 
CCHF licensed in any other EU Member State. 
Conclusions 
CCHF is a disease with a high fatality rate and the 
potential to cause outbreaks. The vector for CCHF, 
the Hyalomma tick is present in southeastern and 
southern Europe. Climate factors may contribute to 
a further spread of the vector and to a consecutive 
extension of the geographic range of CCHF, which may 
further expand to European countries bordering the 
Mediterranean Sea, with the highest risk in neighbour-
ing areas with already established endemicity. This 
highlights the need for strengthening human, vector, 
and veterinary surveillance, especially in areas where 
CCHF is expected to occur in the future. Together with 
the implementation of standardised case definitions 
for CCHF this will allow an estimate of the CCHF bur-
den and of epidemiologic trends in various areas and 
countries. Guidance for contact tracing and the estab-
lishment of early detection and response systems will 
allow prompt interventions at patient, community, and 
hospital level. To enable early detection, laboratory 
capacities are crucial to rapidly confirm the suspected 
clinical diagnosis and besides being available, tests 
need to be reliable and affordable. Overall, laboratory 
capacities for CCHF should increase. Considering the 
high case fatality rate of CCHF, development of a vac-
cine and new drugs against CCHF are of major impor-
tance. Ribavirin efficacy should be assessed through 
well-designed clinical protocols and in endemic areas 
general public and health-care workers should be 
aware about modes of CCHF transmission and prophy-
lactic measures. Climate and environmental factors 
and human behavior that may influence CCHF epidemi-
ology and spread should be further studied. Mapping 
of endemic areas and risk assessment for CCHF in 
Europe should be completed and areas at risk for CCHF 
expansion should be identified and finally, appropri-
ate tick-control strategies including public education 
should be implemented. All these measures should be 
undertaken as part of a multidisciplinary collaboration 
at interregional and international level and link with 
initiatives such as the International network for capac-
ity building for the control of emerging viral vector-
borne zoonotic diseases: ARBO-ZOONET [29].  
In accordance with an ECDC-initiated assessment on 
the importance of vector-borne diseases in 2008, CCHF 
has been identified as a priority disease for the EU [12]. 
In order to strengthen preparedness and response for 
CCHF and build capacity for its prevention and control, 
it is necessary to identify relevant gaps and work in an 
integrated fashion.
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